Biotech is guessing how Vinay Prasad might change the FDA. His research, writing offer clues.
Across hundreds of published papers, CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might push for higher standards in the review of medicines under his division's purview.
Across hundreds of published papers, CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might push for higher standards in the review of medicines under his division's purview.
